Phase II trial of XELOX plus bevacizumab for metastatic colorectal cancer.

Phase II trial of XELOX plus bevacizumab for metastatic colorectal cancer. - N-SOG 06

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006397

Enrollment

Registered

2011-10-01

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced colorectal cancer

Interventions

XELOX + Bev

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Histopathologically confirmed colorectal cancer (2)Unresectable advanced/metastatic colorectal cancer (3)Age of 20 years or older (4)ECOG performance status 0-1 (5)Alife expectancy greater than 12 weeks (6)Measurable or evaluable disease (RECIST ver.1.1.) (7)Adequate organ function (8) Written informed concent

Exclusion criteria

Exclusion criteria: (1)With brain metastases (2)Uncontrollable peptic ulcer disease (3)Prior chemotherapy with bevacizumab or oxaliplatin (4)Serious complications (5)Multiple malignancies to be treated (6)Severe neuropathy (7)With interstitial lung disease or pulmonary fibrosis (8)Pregnant (9)Previous history of severe drug-induced allergy (10)Disqualified by attending doctor

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Progression free survival,Time to treatment failure,Overall survival,Resection rate,R0 resection rate,Safety	—

Countries

Japan

Contacts

Public ContactKeisuke Uehara

Nagoya University Graduated School of Medicine Division of Surgical Oncology

kuehara@med.nagoya-u.ac.jp052-744-2222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026